Abbott Laboratories has entered into a licensing agreement with India’s Zydus Cadila to market the company’s products in 15 emerging countries.
The move, which will accelerate Abbot’s growth in emerging markets, will help the company gain the rights to at least 24 Zydus products, as well as an option to add a further 40 products.
Go deeper with GlobalData
The collaboration includes access to drugs for pain, cancer, neurological and cardiovascular illnesses, and will leverage off Abbot’s infrastructure to promote Zydus’s large portfolio.
Abbot also announced the creation of a new stand-alone Established Products Division with $5bn in current pharmaceutical sales that will focus solely on fast-growing emerging markets.
The financial terms of the agreement were not disclosed.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
